Jefferies Downgrades Regeneron Pharma (REGN) to Hold, Sees Limited Eylea Upside
Tweet
Share
E-mail
Get Alerts REGN Hot Sheet
Price: $906.54 -0.09%
Rating Summary:
29 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
29 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Jefferies downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Hold with a price target of $179.00.
The firm sees limited Eylea upside after conducting another wAMD survey. The firm said the current stock prices adequately reflects anticipated growth. Benefit from potential cmpding driven decline in Avastin use only modestly benefits Eylea, according to the firm.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $179.40 yesterday.
The firm sees limited Eylea upside after conducting another wAMD survey. The firm said the current stock prices adequately reflects anticipated growth. Benefit from potential cmpding driven decline in Avastin use only modestly benefits Eylea, according to the firm.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $179.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
- Analysts see 'more upside ahead' for Amazon (AMZN) stock
- LKQ Corp. (LKQ) PT Lowered to $60 at Jefferies
Create E-mail Alert Related Categories
DowngradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
